Metastasis is the leading cause of death in lung cancer (LC) patients. Although LC can be treated by surgery, chemotherapy, radiotherapy, targeted therapies, or immunotherapy, the 5 years overall survival of LC patients remains low due to tumor heterogeneity and multidrug resistance. Lung cancer cells frequently spread to bone, liver, lung, and brain, and the metastasis may develop years after successful treatment of the primary tumor. The risk for LC metastasis depends on the biological behavior of the tumor, the stage at the time to be diagnosed, and the treatments used for the primary tumor. Therefore, identification of the molecular and genetic mechanisms associated with metastasis is vital to improve survival outcomes for LC patients. Recently tumor-derived exosomes have attracted much attention because they may play an important role in mediating the formation of the pre-metastatic niche. Targeting exosomes or pre-metastatic niches will be a new direction for the prevention of LC metastasis.
This Research Topic will focus on two aspects: the first is to identify exosomal components which mediate the formation of the pre-metastatic niche (PMN), and the second is to find out strategies that will block the effect of tumor-derived exosomal components and prevent the formation of PMN for LC metastasis. The identification of exosomal components could not only better elucidate the underlying mechanisms of metastasis but also aid in the therapeutic development. The exosomal components may become biomarkers to help predict the prognosis of LC patients. We welcome submissions covering, but not limited to, the following sub-topics:
1. Research on exosome components, especially findings on novel prognostic biomarkers and/or risk factors for prediction of effect on the induction of pre-metastatic niche.
2. Molecular mechanisms of pre-metastatic niche formation and potential targets for preventing metastasis.
3. Prevention of LC metastasis via targeting exosome-induced pre-metastatic niche formation using small molecule chemicals and/or other biological manners.
4. Novel biomarkers include proteins derived from exosomes that predict tumor metastasis, development, etc.
5. Mechanisms of inflammation-cancer transformation and the related predictive markers.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Metastasis is the leading cause of death in lung cancer (LC) patients. Although LC can be treated by surgery, chemotherapy, radiotherapy, targeted therapies, or immunotherapy, the 5 years overall survival of LC patients remains low due to tumor heterogeneity and multidrug resistance. Lung cancer cells frequently spread to bone, liver, lung, and brain, and the metastasis may develop years after successful treatment of the primary tumor. The risk for LC metastasis depends on the biological behavior of the tumor, the stage at the time to be diagnosed, and the treatments used for the primary tumor. Therefore, identification of the molecular and genetic mechanisms associated with metastasis is vital to improve survival outcomes for LC patients. Recently tumor-derived exosomes have attracted much attention because they may play an important role in mediating the formation of the pre-metastatic niche. Targeting exosomes or pre-metastatic niches will be a new direction for the prevention of LC metastasis.
This Research Topic will focus on two aspects: the first is to identify exosomal components which mediate the formation of the pre-metastatic niche (PMN), and the second is to find out strategies that will block the effect of tumor-derived exosomal components and prevent the formation of PMN for LC metastasis. The identification of exosomal components could not only better elucidate the underlying mechanisms of metastasis but also aid in the therapeutic development. The exosomal components may become biomarkers to help predict the prognosis of LC patients. We welcome submissions covering, but not limited to, the following sub-topics:
1. Research on exosome components, especially findings on novel prognostic biomarkers and/or risk factors for prediction of effect on the induction of pre-metastatic niche.
2. Molecular mechanisms of pre-metastatic niche formation and potential targets for preventing metastasis.
3. Prevention of LC metastasis via targeting exosome-induced pre-metastatic niche formation using small molecule chemicals and/or other biological manners.
4. Novel biomarkers include proteins derived from exosomes that predict tumor metastasis, development, etc.
5. Mechanisms of inflammation-cancer transformation and the related predictive markers.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.